MedTrace Logo

Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thrombocytopenia.

Conditions

  • Isolated Chemotherapy-induced Thrombocytopenia

Interventions

BIOLOGICAL

romiplostim

Sponsors & Collaborators

Principal Investigators

  • Cy Wilkins, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-30
Primary Completion
2023-11-13
Completion
2023-11-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052882 on ClinicalTrials.gov